OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Nov 30, 2023 • 15min
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.
Nov 23, 2023 • 11min
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.
Nov 20, 2023 • 8min
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.
Nov 16, 2023 • 13min
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
Nov 13, 2023 • 12min
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on PFS outcomes for patients with pancreatic cancer.
Nov 9, 2023 • 13min
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
Nov 6, 2023 • 12min
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.
Oct 30, 2023 • 15min
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.
Oct 26, 2023 • 7min
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, dMMR disease.
Oct 23, 2023 • 10min
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.
